PMID- 34211566
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - The Effectiveness and Safety of Bushen Huoxue Decoction on Treating Coronary 
      Heart Disease: A Meta-Analysis.
PG  - 5541228
LID - 10.1155/2021/5541228 [doi]
LID - 5541228
AB  - OBJECTIVE: The aim of this meta-analysis was to systematically evaluate the 
      effectiveness and safety of the traditional Chinese medicine (TCM) formula Bushen 
      Huoxue Decoction (BSHXD) in treating coronary heart disease (CHD). METHODS: 
      Randomized controlled trials (RCTS) of BSHXD in treating CHD were searched until 
      March 2020, through six electronic databases: PubMed, Cochrane Library, CNKI, 
      WanFang, SinoMed, and VIP. This study used the Cochrane Risk Test bias tool in 
      the Cochrane Handbook to assess the quality of the methodology. Review Manager 
      (RevMan) 5.3 was used to analyze the results. Grading of Recommendations 
      Assessment, Development, and Evaluation (GRADE) criteria were applied in the 
      classification of evidence quality. RESULTS: Ten RCTs involving 901 patients were 
      finally included in this meta-analysis. It revealed that the effectiveness of 
      BSHXD in treating CHD was significantly better than that of the conventional 
      western medicine (CWM) treatment (P < 0.00001). The effective rate of BSHXD 
      treatment group on ECG was also significantly higher than that of CWM group (P < 
      0.00001). The low-density lipoprotein cholesterol was decreased in the treatment 
      groups compared with those in the control groups (P < 0.00001). There was also a 
      reduction in frequency and duration of angina pectoris (P < 0.00001). There were 
      no significant differences in TC level (P=0.08), TG level (P=0.86), and HDL level 
      (P=0.76) between the treatment and control groups. Five studies had informed 
      adverse events, including nausea and diarrhea. CONCLUSION: Our findings laid the 
      foundation to the use of TCM Formula BSHXD in combination with conventional 
      western medicine for treating CHD. However, due to the limitation of the quality 
      of the included researches, in addition to potential reporting bias, the above 
      conclusions still need verification by higher-quality and better-designed 
      studies.
CI  - Copyright (c) 2021 Lan-Chun Liu et al.
FAU - Liu, Lan-Chun
AU  - Liu LC
AUID- ORCID: 0000-0002-2093-7664
AD  - Cardiovascular Department, Guang'anmen Hospital of China Academy of Chinese 
      Medical Sciences, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Mao, Qi-Yuan
AU  - Mao QY
AUID- ORCID: 0000-0002-3686-2847
AD  - Department of Oncology, Guang'anmen Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Liu, Chao
AU  - Liu C
AUID- ORCID: 0000-0003-1806-9930
AD  - Cardiovascular Department, Guang'anmen Hospital of China Academy of Chinese 
      Medical Sciences, Beijing, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Hu, Jun
AU  - Hu J
AUID- ORCID: 0000-0002-7569-3433
AD  - Cardiovascular Department, Guang'anmen Hospital of China Academy of Chinese 
      Medical Sciences, Beijing, China.
FAU - Duan, Lian
AU  - Duan L
AUID- ORCID: 0000-0001-8561-5212
AD  - Cardiovascular Department, Guang'anmen Hospital of China Academy of Chinese 
      Medical Sciences, Beijing, China.
FAU - Wang, Jie
AU  - Wang J
AUID- ORCID: 0000-0002-2178-5148
AD  - Cardiovascular Department, Guang'anmen Hospital of China Academy of Chinese 
      Medical Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210609
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8208867
COIS- All authors declare that there are no conflicts of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/03 06:01
PMCR- 2021/06/09
CRDT- 2021/07/02 06:38
PHST- 2021/01/31 00:00 [received]
PHST- 2021/05/24 00:00 [accepted]
PHST- 2021/07/02 06:38 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/03 06:01 [medline]
PHST- 2021/06/09 00:00 [pmc-release]
AID - 10.1155/2021/5541228 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Jun 9;2021:5541228. doi: 
      10.1155/2021/5541228. eCollection 2021.